Eiger BioPharmaceuticals, Inc

At close
No trades
See on super-charts

Key stats

Market capitalization
42.67MUSD
Dividends yield (FY)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
−2.3370USD

About Eiger BioPharmaceuticals, Inc

ISIN
US28249U1051
CEO
David Apelian
Headquarters
Palo Alto
Employees
56
Founded
2008

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:
‪0‬
Revenue
‪0‬

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more